NUVBNuvation Bio Inc - Ordinary Shares - Class A
$4.90
$0.14
(2.94%)
Pre-Market
EarningsAug 6
Mkt Cap$1.6B
Vol593.00
Fundamentals
Mkt Cap
$1.6B
Volume
-
52W High
$9.75
52W Low
$1.57
PE Ratio
-11.12
Avg. Volume
4.53M
EPS (Annual)
-$0.5991
Rev/Employee
$211,080.54
Earnings
Aug 06
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Nuvation Bio to Present at the Jefferies Global Healthcare Conference Nuvation Bio to Present at the Jefferies Global Healthcare Conference PR Newswire NEW YORK, May 27, 2026 NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of...
PR Newswire
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer...
PR Newswire
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio to Collaborate with Thermo Fisher...
PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of...
PR Newswire
Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio to Participate in Upcoming Investor Conferences Nuvation Bio to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, May 5, 2026 NEW YORK, May 5, 2026 /PRNewswire...
PR Newswire
Nuvation Bio's (NUVB) "Outperform" Rating Reaffirmed at Royal Bank Of Canada
Royal Bank Of Canada reaffirmed an 'outperform' rating and set a $20.00 target price on shares of Nuvation Bio in a report on Tuesday...
MarketBeat
Nuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from Wedbush
Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price on shares of Nuvation Bio in a research report on Tuesday...
MarketBeat
Nuvation Bio Q1 Earnings Call Highlights
Nuvation Bio (NYSE:NUVB) executives said the company made continued commercial progress with ROS1-positive non-small cell lung cancer (NSCLC) therapy Ibtrozi during the first quarter of 2026...
MarketBeat
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of -91.30% and +0.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Nuvation Bio (NYSE:NUVB) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS
Nuvation Bio (NYSE:NUVB - Get Free Report) issued its earnings results on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.04. The business had revenue of $83.23 million for the quarter, compared to analyst estimates of...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest NUVB News
ViewNuvation Bio to Present at the Jefferies Global Healthcare Conference
PR Newswire
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
PR Newswire
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer
PR Newswire
Advertisement|Remove ads.